Interaction between ferric carboxymaltose and denosumab causing severe hypocalcaemia and hypophosphataemia in a patient without chronic kidney disease

被引：1

作者：

Muhandiramge, Jaidyn ^{[1
,2
]}

Lee, Vivian ^{[2
]}

Tran, Monica ^{[2
]}

Ho, Lannie ^{[2
]}

机构：

[1] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia

[2] Austin Hlth, Melbourne, Vic, Australia

来源：

INTERNAL MEDICINE JOURNAL | 2023年 / 53卷 / 07期

关键词：

ferric carboxymaltose; denosumab; hypocalcaemia; hypophosphataemia; osteoporosis; IRON;

D O I：

10.1111/imj.16156

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coadministration of ferric carboxymaltose and denosumab may cause hypocalcaemia and hypophosphataemia; however, this interaction is not well-described in the literature and has typically been described in patients with chronic kidney disease (CKD). We present a case of this interaction in a patient without preexisting CKD. We suggest the use of alternative iron preparations and an interval of at least 4 weeks between administrations.

引用

页码：1273 / 1276

页数：4

共 50 条

[1] Denosumab/ferric-carboxymaltose interactionSevere hypocalcaemia and hypophosphataemia : case report
Reactions Weekly, 2023, 1976 (1) : 128 - 128
[2] Hypocalcaemia and hypophosphataemia following denosumab and IV ferric carboxymaltose in an older patient with normal renal function
Tai, Rebecca
Mouchaileh, Nadia
Ting, Celia
JOURNAL OF PHARMACY PRACTICE AND RESEARCH, 2022, 52 (01) : 49 - 52
[3] Severe hypophosphataemia and hypocalcaemia following intravenous ferric derisomaltose and denosumab administration
Kritzinger, Justin
Wyse, Jonathan
Karaplis, Andrew
BMJ CASE REPORTS, 2024, 17 (12)
[4] Denosumab/ferric-carboxymaltoseSevere hypocalcaemia following drug-drug interaction and hypophosphataemia
Reactions Weekly, 2024, 2003 (1) : 320 - 320
[5] Denosumab/ferric-carboxymaltose interactionsHypocalcaemia and hypophosphataemia following drug interaction : case report
Reactions Weekly, 2022, 1901 (1) : 200 - 200
[6] Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction
Smyth, B.
Ong, S.
INTERNAL MEDICINE JOURNAL, 2016, 46 (03) : 360 - 363
[7] Denosumab-related hypocalcaemia in chronic kidney disease
Yong, Chen Han
AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2018, 47 (08) : 538 - 539
[8] Severe hypophosphataemia following ferric carboxymaltose infusion in paediatric patients with inflammatory bowel disease
Harris, Rachel Elizabeth
Armstrong, Lawrence
Curtis, Lee
Garrick, Vikki
Gervais, Lisa
Tayler, Rachel
Hansen, Richard
Russell, Richard
FRONTLINE GASTROENTEROLOGY, 2020, 11 (04) : 324 - 326
[9] PRESCRIBER BEWARE: SEVERE HYPOCALCAEMIA AFTER DENOSUMAB AND IRON INFUSION IN CHRONIC KIDNEY DISEASE
Cohen, A. W. S.
Chacko, B.
NEPHROLOGY, 2021, 26 : 51 - 51
[10] DENOSUMAB ASSOCIATED SEVERE HYPOCALCEMIA IN A PATIENT WITH CHRONIC KIDNEY DISEASE
Williams, M. H.
Williams, R. A.
Salim, S.
Sheehan, N.
JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (02) : 486 - 486

← 1 2 3 4 5 →